Tirzepatide is not approved for insulin resistance, but the research points in a helpful direction. It lowers blood sugar in type 2 diabetes, it drives large weight loss, and over three years it cut progression from prediabetes to type 2 diabetes by 94%. No trial in our sources measured insulin resistance itself as a main outcome, so this page does not print an insulin-sensitivity number. If you are new to the drug, start with our tirzepatide guide.
Key takeaways
- Neither tirzepatide label lists "insulin resistance" as an indication. Mounjaro is for blood sugar control in type 2 diabetes; Zepbound is for chronic weight management and obstructive sleep apnea.
- In SURPASS-1, tirzepatide alone lowered A1c by 1.87 to 2.07 points over 40 weeks, versus a 0.04 point rise on placebo.
- In SURPASS-2, tirzepatide beat semaglutide 1 mg on both A1c and weight at 40 weeks.
- In the SURMOUNT-1 three-year extension, 1.3% of adults with prediabetes on tirzepatide progressed to type 2 diabetes, versus 13.3% on placebo.
- Taken with insulin or a sulfonylurea, tirzepatide raises the risk of low blood sugar; the label says those drugs may need a dose reduction.
What insulin resistance is, in plain English
Insulin is the hormone that tells your cells to take sugar out of the blood and use it or store it. Insulin resistance means the cells respond less to that signal. The pancreas answers by making more insulin to get the same job done. For a while that works and blood sugar stays normal. Over time the pancreas can fall behind, blood sugar rises, and the result is prediabetes and then type 2 diabetes.
Two things make insulin resistance hard to talk about precisely. First, there is no simple routine blood test for it; clinics usually infer it from fasting sugar, A1c, and body weight. Second, drug trials almost never use it as their main endpoint. They measure A1c, a blood test that reflects average blood sugar over the previous few months, and they measure weight. Those are the numbers this page can give you.
How tirzepatide works on GIP and GLP-1
Tirzepatide is a single molecule that activates two gut hormone receptors, GIP and GLP-1. Both hormones are released after you eat. Acting on them does three things that matter for blood sugar and weight:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Glucose-dependent insulin release. The drug prompts the pancreas to release insulin when blood sugar is high, and much less when it is not. That "only when needed" pattern is why tirzepatide on its own carries a low risk of low blood sugar.
- Slower stomach emptying. Food leaves the stomach more slowly, so sugar enters the blood more gradually after meals.
- Less appetite. People eat less and lose weight. Because excess weight is a major driver of insulin resistance, weight loss is the most likely route by which tirzepatide improves how the body handles insulin, even though the trials did not measure that directly.
For the mechanism in more depth, read how tirzepatide works.
Tirzepatide and insulin resistance: what SURPASS-1 shows
SURPASS-1 tested tirzepatide on its own, without other diabetes drugs, in adults with type 2 diabetes over 40 weeks. The main outcome was the change in A1c.
| SURPASS-1 arm (40 weeks) | Change in A1c (percentage points) |
|---|---|
| Tirzepatide 5 mg | -1.87 |
| Tirzepatide 10 mg | -1.89 |
| Tirzepatide 15 mg | -2.07 |
| Placebo | +0.04 |
Source: SURPASS-1, Rosenstock et al., Lancet 2021.
An A1c drop of about 2 points from a single drug, with no insulin and no other agents, is a large change. It tells you the body was handling sugar far better on the drug. It does not tell you how much of that came from better insulin sensitivity versus more insulin release or slower digestion, because the trial was not built to separate those.
Tirzepatide vs semaglutide: SURPASS-2
SURPASS-2 compared tirzepatide with semaglutide 1 mg, a GLP-1 only drug, in adults with type 2 diabetes over 40 weeks.
| SURPASS-2 arm (40 weeks) | Change in A1c (percentage points) | Change in body weight (kg) |
|---|---|---|
| Tirzepatide 5 mg | -2.01 | -7.6 |
| Tirzepatide 10 mg | -2.24 | -9.3 |
| Tirzepatide 15 mg | -2.30 | -11.2 |
| Semaglutide 1 mg | -1.86 | -5.7 |
Source: SURPASS-2, Frias et al., NEJM 2021.
Every tirzepatide dose lowered A1c more than semaglutide 1 mg, and every dose produced more weight loss. That pattern, better sugar control plus more weight loss, is consistent with a bigger effect on the conditions that drive insulin resistance, without proving it. For the wider comparison, see semaglutide vs tirzepatide.
Prediabetes: the SURMOUNT-1 three-year extension
This is the study closest to the insulin resistance question. SURMOUNT-1 enrolled adults with obesity or overweight and no diabetes. Those who had prediabetes at the start were followed for 176 weeks, about three years and four months, on tirzepatide or placebo. The question was how many developed type 2 diabetes.
| SURMOUNT-1 extension, adults with prediabetes (176 weeks) | Tirzepatide | Placebo |
|---|---|---|
| Progressed to type 2 diabetes | 1.3% | 13.3% |
| Relative reduction in progression | 94% | Reference |
| Change in body weight (15 mg vs placebo) | -22.9% | -2.1% |
Source: SURMOUNT-1 three-year extension, Jastreboff et al., NEJM 2025.
Prediabetes is, in most people, insulin resistance that the pancreas can still partly cover. Stopping the slide into diabetes is the practical goal of treating it. In this study, tirzepatide cut that slide by 94% while people lost close to a quarter of their body weight at the top dose. That is strong evidence for the outcome that matters. It is still not a direct measurement of insulin sensitivity, and the drug is not approved for prediabetes.
What the labels do and do not say
| Brand | Approved indication | Insulin resistance on the label? |
|---|---|---|
| Mounjaro | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. | No |
| Zepbound | Chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity. | No |
| Compounded tirzepatide | Not FDA approved for any use. | No label |
Source: Mounjaro and Zepbound prescribing information (DailyMed).
A prescriber can still decide the drug fits a person with insulin resistance, prediabetes, or weight-related conditions. That is a clinical judgment, and when the person meets the Zepbound weight criteria it is on-label. Prescribing for "insulin resistance" alone is off-label, and insurance plans usually look for a diagnosis that matches the label.
Why this page does not print an insulin-sensitivity number
You may see pages that quote a precise percentage improvement in insulin sensitivity from tirzepatide. The trials in our source list, SURPASS-1 through SURPASS-5, SURMOUNT-1 through SURMOUNT-5, SURMOUNT-OSA and the SURMOUNT-1 extension, did not use insulin sensitivity as a primary endpoint. Any such figure would come from a smaller study or a secondary analysis we have not verified against a label or a listed publication, so it is not printed here. The A1c, weight and diabetes-progression numbers above are what the record supports.
The hypoglycemia warning with insulin or sulfonylureas
On its own, tirzepatide releases insulin mostly when blood sugar is high. Insulin injections and sulfonylureas (a class of diabetes pills that push the pancreas to release insulin regardless of sugar level) do not have that safeguard. Both labels warn that using tirzepatide with insulin or an insulin secretagogue raises the risk of hypoglycemia, and that a dose reduction of those drugs may be needed. If you take either, tell your prescriber before starting. Do not adjust any dose yourself. Sweating, shakiness, confusion or waking at night with a racing heart are reasons to check your sugar and call. Related pages: tirzepatide drug interactions and does tirzepatide lower blood pressure.
What this means for compounded tirzepatide
Compounded tirzepatide is not FDA approved for insulin resistance, prediabetes, diabetes or any other use, and it is not interchangeable with Mounjaro or Zepbound. Every number on this page comes from the branded product's trials. The molecule is the same, so the same hypoglycemia caution with insulin or sulfonylureas applies, and the same "ask your prescriber" rule covers any dose change. A licensed provider decides whether a compounded medication is appropriate for you. FormBlends compounded tirzepatide is $149 for the first month, then $239 per month, or $214 per month with Subscribe & Save, with the same price at every dose. See pricing or begin the assessment.
Frequently Asked Questions
Does tirzepatide help with insulin resistance?
Indirectly, the evidence says yes: it lowers A1c by about 2 points in type 2 diabetes, produces large weight loss, and cut progression from prediabetes to diabetes by 94% over three years. No trial in our sources measured insulin resistance directly as a main outcome, so there is no insulin-sensitivity number to quote.
Is tirzepatide approved for insulin resistance?
No. Mounjaro is approved for blood sugar control in adults with type 2 diabetes. Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. Neither label mentions insulin resistance.
Can tirzepatide prevent type 2 diabetes if I have prediabetes?
In the SURMOUNT-1 three-year extension, 1.3% of adults with prediabetes on tirzepatide developed type 2 diabetes, versus 13.3% on placebo, a 94% reduction. The drug is not approved for prediabetes, so this is off-label unless you also meet the Zepbound weight criteria.
Does tirzepatide work better than semaglutide for blood sugar?
In SURPASS-2, all three tirzepatide doses lowered A1c more than semaglutide 1 mg (2.01 to 2.30 points versus 1.86) and produced more weight loss (7.6 to 11.2 kg versus 5.7 kg) over 40 weeks. That trial used the 1 mg diabetes dose of semaglutide, not the higher weight-loss dose.
Can tirzepatide cause low blood sugar?
On its own, rarely, because it releases insulin mostly when sugar is high. Combined with insulin or a sulfonylurea, the risk goes up, and the label says those drugs may need a lower dose. Talk to your prescriber before combining them.
Sources
- Mounjaro (tirzepatide) prescribing information, DailyMed, National Library of Medicine, revised 08/2026.
- Zepbound (tirzepatide) prescribing information, DailyMed, National Library of Medicine, revised 08/2026.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1), Rosenstock et al., Lancet, 2021.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2), Frias et al., New England Journal of Medicine, 2021.
- Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 three-year extension), Jastreboff et al., New England Journal of Medicine, 2025.
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5), Dahl et al., JAMA, 2022.
Next steps
Browse the tirzepatide hub for every other tirzepatide question. Talk to a clinician about your A1c, your weight and any diabetes medicines you already take before deciding whether tirzepatide fits. Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; a licensed provider decides whether it is appropriate for you.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →